ABBV
AbbVie Inc.
AbbVie (ABBV) Q2 2026 earnings
Published Jul 31, 2026
AI summary
- Revenue $16.99B, up 10% from $15.42B a year ago.
- Adjusted EPS $3.65 beat the $3.61 consensus by $0.04, up from $2.97 a year ago.
- AbbVie reported second-quarter revenue of $16.99 billion, a 10.2% increase compared to the prior year.
- GAAP diluted EPS rose to $2.03, while adjusted diluted EPS grew 22.9% to $3.65.
- Immunology and neuroscience portfolios drove growth, offsetting declines in oncology and aesthetics.
Results vs analyst consensus
Revenue
Reported
$16.99B
Consensus not captured before release
+10% YoY
Adjusted EPS
Reported · Adjusted diluted EPS
$3.65
Consensus $3.61
Beat by $0.04GAAP EPS: $2.03
Consensus: Yahoo Finance · Q2 2026 · EPS estimate at release
Revenue display rounded; difference uses exact result.
Next quarter outlook
$13.87–$14.07
full year 2026 EPS guidance (non-GAAP)
Next-quarter consensus not captured before release.
What to watch
- Global Humira net revenues decreased 35.9% on a reported basis.
- Results include an unfavorable impact of $0.17 per share related to acquired IPR&D and milestones expense.
- The 2026 guidance includes a $0.14 per share dilutive impact from the proposed Apogee Therapeutics acquisition.
Read original report
Source: AbbVie Inc. press release · SEC Form 8-K exhibit 99.1